It is made available under a CC-BY-NC-ND 4.0 International license .

Cash Transfer Programs and HIV-Related Outcomes: an Analysis of 42 Countries from 1996 to 2019

Aaron RICHTERMAN MD,¹ Harsha THIRUMURTHY PhD²

Running Title: Cash Transfers and HIV-Related Outcomes

Keywords: HIV, Cash Transfers, Poverty Reduction, Social Protection

Abbreviations: CCT, Conditional cash transfer; CI, Confidence Interval; DHS, Demographic and Health Survey; IRR, incidence rate ratio; LMIC, low- and middle-income countries; OR, odds ratio; PEPFAR, President's Emergency Plan for AIDS Relief; UCT, unconditional cash transfer; UNAIDS, The Joint United Nations Programme on HIV/AIDS

Word count: 4,699 Number of references: 48 Number of tables: 2 Number of figures: 4

Corresponding Author: Aaron Richterman, MD, MPH; Hospital of the University of Pennsylvania, 3400 Spruce Street, Philadelphia, PA 19104; e-mail: aaron.richterman@pennmedicine.upenn.edu telephone: 2674417915

¹ Division of Infectious Diseases, Hospital of the University of Pennsylvania, Philadelphia, PA, USA

² Department of Medical Ethics and Health Policy, University of Pennsylvania, Philadelphia, PA

It is made available under a CC-BY-NC-ND 4.0 International license .

1 Abstract

2 Background

3 Many low- and middle-income countries have introduced cash transfer programs as part of their

4 poverty reduction and social protection strategies. These programs have the potential to

5 overcome various drivers of HIV risk behaviors and usage of HIV services, but their overall

6 effects on a broad range of HIV-related outcomes remains unknown.

7 Methods

8 We used publicly reported data to determine whether low- and middle-income countries with 9 HIV prevalence >1% and baseline annual incidence >1/1000 had conditional or unconditional 10 cash transfer programs that covered >5% of the impoverished population, and the year in which 11 those programs began and ended. We obtained country- and individual-level data on HIV-related 12 outcomes from UNAIDS and population-representative household surveys, focusing on the 13 period between 1996 and 2019. We conducted difference-in-differences analyses with country 14 and year fixed effects to evaluate the effects of cash transfer programs on country- and 15 individual-level HIV-related outcomes.

16 Findings

Forty-two countries across three continents were included. Among these, 21 were in the
intervention group, having implemented cash program(s) with impoverished population coverage
greater than 5% during the study period. Cash transfer programs were associated with lower
probability of reporting sexually transmitted infection within the last 12 months among females
(odds ratio [OR] 0.67, 95% confidence interval [CI] 0.50-0.91) and higher probability of an HIV

It is made available under a CC-BY-NC-ND 4.0 International license .

- test within the last 12 months among females (OR 2.61, 95% CI 1.15-5.88) and males (OR 3.19,
- 23 95% CI 2.45-4.15). For country-level outcomes, cash transfer programs were associated with a
- reduction in new HIV infections (incidence rate ratio [IRR] 0.94, 95% CI 0.89-0.99), but not
- with the proportion of people with HIV receiving antiretroviral therapy (5.0%, 95% CI -0.2-10.1)
- or AIDS-related deaths (IRR 0.99, 95% CI 0.95-1.03), though temporal analyses showed delayed
- 27 improvements in both antiretroviral coverage and deaths.

28 Interpretations

- 29 Cash transfer programs, which are being expanded in the context of the COVID-19 pandemic,
- 30 have the potential to promote ongoing efforts to end HIV as a public health threat. Alongside the
- 31 already existing focus on expanding biomedical services, these anti-poverty programs can play a

32 greater role in achieving global targets for HIV prevention and treatment.

33 Funding

34 None

It is made available under a CC-BY-NC-ND 4.0 International license .

35 Introduction

36 HIV continues to be a major global public health threat, causing an estimated 1.7 million new infections and 690,000 AIDS-related deaths in 2019.¹ The Joint United Nations Programme on 37 38 HIV/AIDS (UNAIDS) Fast Track plan set the goal in 2014 of reducing annual infections to 200,000 and AIDS-related deaths by 90% by 2030.² In addition to the rapid scaling up of clinical 39 40 services, the Fast Track plan also emphasizes the importance of expanding social protection for achieving these objectives.³ Social protection is thought to be important because of the well-41 42 documented relationship between poverty or economic inequality and risk factors for HIV 43 transmission (e.g., transactional sex among adolescent girls and young women, earlier age at sexual debut, lower use of HIV services, and worse antiretroviral adherence) and HIV-related 44 morbidity and mortality.⁴⁻¹² 45

46 Over the past two decades, many low- and middle-income countries (LMICs) have introduced 47 cash transfer programs as central components of their poverty reduction and social protection 48 strategies. These programs, which range from conditional cash transfer (CCT) programs that are 49 common in Latin America to unconditional cash transfer (UCT) programs that are common in 50 sub-Saharan Africa, exist in over 100 LMICs, and many countries have expanded or introduced 51 new programs during the COVID-19 pandemic. A growing evidence base suggests that cash 52 transfer programs reduce poverty, foster economic autonomy, raise school attendance for 53 children, improve empowerment for women, and increase health service use, among other 54 benefits.¹³ Conceptually, cash transfer programs may improve outcomes by increasing income 55 and addressing economic barriers as well as by alleviating the psychological impacts of poverty on mental bandwidth and decision-making.¹⁴⁻¹⁹ 56

It is made available under a CC-BY-NC-ND 4.0 International license .

57 Despite the existence of cash transfer programs in many countries with generalized HIV 58 epidemics and the large number of evaluations of these programs, relatively few studies have 59 examined their effects on HIV-related outcomes at the individual or population level. Several 60 studies of predominantly smaller-scale cash transfer interventions have examined the direct 61 effects on beneficiaries and shown mixed but generally favorable changes in HIV-related 62 outcomes. For HIV prevention, a few randomized controlled trials of cash transfers have focused 63 on adolescent girls and young women. In Malawi, a cash transfer intervention for schooling reduced HIV prevalence among schoolgirls.²⁰ In South Africa, conditional cash transfers for 64 65 schooling had no effect on HIV incidence among adolescent girls and young women, although 66 the control group in this study received cash transfers and school attendance was high in both study groups.²¹ No randomized controlled trials have studied the impact of unconditional cash 67 68 transfer programs, which are more commonly used by governments in sub-Saharan Africa, on 69 HIV incidence. Non-experimental impact evaluations of the Kenyan government's cash transfer 70 program for caregivers of orphans and vulnerable children and another of the Malawi government's household cash transfer program found delays in sexual debut.^{22,23} Finally, a much 71 72 larger literature has examined the effects of financial and non-financial incentives that are 73 tailored to specific HIV-related behaviors, but the incentive amounts are typically much smaller 74 than the size of cash transfers typically administered in LMICs. The typical magnitude of these 75 differences can be illustrated in Tanzania, where financial incentives conditional on HIV clinic 76 attendance were studied for six months in 2018 with a maximum total transfer of about 2% of Gross Domestic Product (GDP) per capita, versus the national Productive Social Safety Net 77 Programme, which provides about 12% of GDP per capita annually to poor households.^{24,25} 78 79 Studies of incentives have had mixed results, as some have demonstrated improvements in HIV

It is made available under a CC-BY-NC-ND 4.0 International license .

testing uptake,²⁶⁻²⁹ retention in care,^{25,30,31} adherence to antiretroviral therapy,³¹⁻³³ and virologic
suppression,^{25,34} while others have not.^{30,35-37} An evaluation of large-scale cash transfer programs
using cross population-level data from many different countries remains an important gap in the
literature. An advantage of using population-level data when evaluating cash transfer programs
(rather than using data from cash transfer beneficiaries alone) is that it will be possible to detect
spillover effects of cash transfers, especially if the transfers influence health behaviors that affect
the risk of HIV acquisition and transmission.

We hypothesized that larger, more generalized cash transfer programs might improve both
population and individual HIV-related outcomes. While national cash transfer programs in subSaharan Africa are more commonly unconditional and less HIV-specific than those considered in
the studies described above, benefits may still be seen because of their more expansive reach and
spillover effects stemming from reduced HIV transmission. These national cash transfer
programs also tend to persist over time, compared to financial incentive or cash transfer studies
in which interventions have tended to be time limited.

94 However, few studies have evaluated the broader effects of large-scale cash transfer programs, a

95 policy-relevant topic given the burden of HIV and growing reliance on cash transfer programs.

96 To address this unanswered question, we conducted a difference-in-differences analysis

- 97 evaluating the effects of cash transfer programs on country- and individual-level outcomes in 42
- 98 countries with generalized HIV epidemics from 1996 to 2019.

99 Methods

It is made available under a CC-BY-NC-ND 4.0 International license .

We included all countries with HIV incidence greater than 1 per 1000 persons in 1996 and HIV
prevalence greater than 1% in at least one year between 1996 and 2019,¹ a period when many
countries introduced cash transfer programs.

103 *Data*

We identified all major cash transfer programs within included countries. We manually searched a variety of sources, detailed in the Supplementary Appendix, to identify the programs and determine the year in which they were introduced, target population, whether they were conditional or unconditional, amount of transfer, and the most recently available number of beneficiaries. For each cash transfer program, we estimated the most recent impoverished population coverage by dividing the total number of beneficiaries by the number of people living below the international poverty line (Supplementary Appendix).

For individual-level data on HIV outcomes, we used the Demographic and Health Surveys
(DHS), which are nationally representative cross-sectional household surveys conducted every 5
years in many LMICs (Supplementary Appendix). Information was obtained for household and
individual characteristics for all female household members of reproductive age (15-49 years)

and a subset of males of reproductive age (typically 15-49, 54, or 59 years). We also used AIDS

116 Indicator Surveys (AIS), which are similar household surveys focused on HIV knowledge,

117 attitudes, behavior, and prevalence. We used DHS or AIS data from any country that met

eligibility criteria and any year between 1996 and 2019.

119 For country-level HIV statistics, we relied on UNAIDS annual estimates that are generated with

120 modeling techniques based on representative population-based surveys and surveillance studies.¹

121 We obtained country and year UNAIDS estimates for the number of new HIV infections, the

It is made available under a CC-BY-NC-ND 4.0 International license .

number of AIDS-related deaths, and proportion of people with HIV receiving antiretroviraltherapy.

124 We obtained additional time-varying covariates for each country and year that were likely to be 125 associated with changes in cash transfer programs and HIV outcomes: Gross Domestic Product (GDP) per capita,³⁸ President's Emergency Plan for AIDS Relief (PEPFAR) funding budgeted 126 per capita,³⁹ The Global Fund to Fight AIDS, Tuberculosis and Malaria disbursements for HIV-127 related programs per capita,⁴⁰ and six Worldwide Governance Indicators from The World Bank 128 129 that are composite indicators based on 30 data sources: Voice and Accountability, Political 130 Stability and Absence of Violence, Government Effectiveness, Regulatory Quality, Rule of Law, and Control of Corruption.³⁸ 131

132 Statistical Analysis

133 We performed difference-in-differences analyses using multivariable regression models to 134 compare trends in HIV-related outcomes in countries with cash transfer programs to those in the 135 same countries prior to cash transfer program introduction and to those in comparison countries 136 without cash transfer programs. Our analysis was developed based on a proposed causal 137 framework linking cash transfer programs to HIV-related outcomes, mediated through an effect 138 on poverty (Figure 1). Our primary explanatory variable of interest was a binary variable 139 indicating presence in a given year of a cash transfer program (or combination of programs) for 140 which the number of beneficiaries exceeded 5% of the population living below the poverty line (Supplementary Appendix).³⁸ Our choice of 5% impoverished population coverage as the 141 142 threshold for our intervention group was subjective but chosen empirically as the smallest likely 143 coverage with which we might expect to see population effects.

It is made available under a CC-BY-NC-ND 4.0 International license .

144	We examined the association between cash transfer programs and both individual- and country-
145	level outcomes. For individual-level outcomes, the unit of observation was a surveyed person in
146	a given country during a given year, and we stratified individual-level outcomes by sex.
147	Individual-level outcomes included the continuous variable age at sexual debut among youths
148	and the binary variables sexually transmitted infection within the prior 12 months, greater than
149	one sexual partner within the prior 12 months, HIV test within the prior 12 months, transactional
150	sex within the prior 12 months, and condom use during the last sexual encounter. The
151	transactional sex outcome was only analyzed for males because this question was only recently
152	added to the female questionnaire in the DHS and there were not enough observations for
153	meaningful comparisons.
154	For country-level outcomes, the unit of observation was the country-year. Country-level
155	outcomes included the number of new HIV infections, the number of AIDS-related deaths, and
156	the proportion of people with HIV receiving antiretroviral therapy.
157	We estimated linear regression models for continuous outcomes, logistic regression models for
158	binary outcomes, and negative binomial regression models for outcomes aggregated as counts.
159	We included fixed effects for each country, which adjusted for measured and unmeasured time-
160	invariant differences between countries, and for each year, which controlled for secular trends in
161	the outcomes across all countries. We used robust standard errors clustered at the country level.
162	For all outcomes, we included additional time-varying, country-level covariates of GDP per
163	capita, PEPFAR funding per capita, HIV-related disbursements by The Global Fund per capita,
164	and three World Bank Worldwide Governance Indicators (Control of Corruption, Political
165	Stability and Absence of Violence, and Voice and Accountability). The other three World Bank
166	Worldwide Governance Indicators (Government Effectiveness, Regulatory Quality, and Rule of

It is made available under a CC-BY-NC-ND 4.0 International license .

Law) were not included because of collinearity (Supplementary Appendix). For individual-level
outcomes, we included additional covariates – age, single marital status, education, wealth
quintile, and rural/urban household setting – and used survey commands to apply sampling
probability weights.

171 We performed several secondary and sensitivity analyses to better characterize the association 172 between cash transfer programs and HIV-related outcomes. First, because country-level 173 outcomes were available annually, we evaluated the temporal relationship between cash transfer 174 programs and country-level outcomes by creating a series of binary indicators for each year after 175 the cash transfer period began. Second, we explored whether there were interactions between 176 cash transfer programs and having above-median HIV prevalence (>3.7%) at the start of the cash 177 transfer program. Third, we did a similar interaction analysis based on whether a country's cash 178 transfer program had above-median coverage (>23% of the population living below the poverty 179 line). Fourth, we stratified models for individual-level outcomes by wealth quintile. Fifth, while 180 our models controlled for PEPFAR and Global Fund spending, to further ensure there was no 181 major collinearity contributing to our findings we used PEPFAR funding per capita and HIV-182 related Global Fund disbursements per capita as outcomes in our primary models to assess for 183 correlation with cash transfer programs. Sixth, we assessed whether individual countries might 184 be outliers for key outcomes by assessing whether estimates changed substantially after 185 excluding each individually.

186 The difference-in-differences design is quasi-experimental and relies on the parallel trends 187 assumption, which is that in the absence of the implementation of cash transfer programs, trends 188 in outcomes would be similar in the intervention and comparison countries. We tested whether 189 intervention and comparison countries had similar trends in the pre-cash transfer period by

It is made available under a CC-BY-NC-ND 4.0 International license .

190 estimating regression models using only data prior to the cash transfer period in each country and 191 including an interaction term between an indicator of whether the country was in the intervention 192 group and a linear time trend. We tested the parallel trends assumption for outcomes with 193 significant findings in our primary analysis. We further evaluated pre-trends in the country-level 194 outcomes by including binary indicators for the four years prior to the cash transfer period in the 195 previously mentioned temporal analysis. Using a temporal analysis to visualize pre-trends for the 196 individual-level outcomes (which were measured in survey) is more difficult because annual 197 survey data were not available for countries. As a result, sample sizes vary greatly by year. We 198 attempted to mitigate this issue somewhat by categorizing multiple years together to allow for 199 greater interpretability, but temporal trends for the individual-level outcomes should be 200 interpreted with caution.

Recent advances in difference-in-differences analyses with variation in intervention timing have
 shown that estimates may be biased particularly if there is heterogeneity in intervention effect
 over time.^{41,42} We conducted a series of additional analyses to assess for the presence and
 magnitude of this potential bias,⁴³ detailed in the Supplementary Appendix.

Additional details on the regression models are available in the Supplementary Appendix. We performed statistical analysis using SAS V.9.4 and R V.3.5.2 using the ggplot2 package.

207 Data Availability Statement

208 Analyzed data can be requested from the DHS program website

209 (https://www.dhsprogram.com/Data/) or are publicly available from UNAIDS

210 (http://aidsinfo.unaids.org/), The World Bank (https://data.worldbank.org/data-catalog/),

It is made available under a CC-BY-NC-ND 4.0 International license .

- 211 PEPFAR (https://data.pepfar.gov/financial), and The Global Fund (https://data-
- 212 <u>service.theglobalfund.org/downloads</u>).
- 213 Code Availability Statement
- 214 Analysis code is available upon request to the corresponding author.
- 215 Role of the Funding Source
- 216 None

217 Results

- Forty-two countries were eligible for inclusion in this study 36 (86%) in Africa, 4 (10%) in
- Latin America and the Caribbean, and 2 (5%) in Asia (Table 1, Supplementary Figures 1-3).
- Among these, 21 countries implemented an eligible cash transfer program (or combination of
- 221 cash transfer programs) at some point during the study period (Figure 1). In these countries, there
- 222 were 36 cash transfer programs 28 were unconditional and eight were conditional
- 223 (Supplementary Table 1). The median total coverage level for cash transfer programs in the
- intervention group was 23% of the impoverished population (IQR 14-63%) and the median HIV
- prevalence at the beginning of the cash transfer period was 3.7% (IQR 1.5-10.7%).
- At the start of the study period, intervention countries had higher HIV prevalence (median 4.1%
- vs 1.7%) and annual HIV incidence rate (median 3.8 vs 2.2 per 1,000 persons) relative to
- 228 comparison countries, but there was no difference between them in any of the six World Bank
- 229 Governance Indicators (Table 1). All countries received some HIV-related Global Fund

medRxiv preprint doi: https://doi.org/10.1101/2021.12.16.21267921; this version posted December 17, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

 disbursements during the study period, and 16 (76%) intervention countries relative to 8 control countries received PEPFAR funding at some point during the study period. We obtained individual survey data from 99 DHS and 6 AIS conducted in included cou during the study period – 24 during intervention years and 82 during comparison years in 1). There were 1,885,733 survey respondents in total, of whom 1,295,177 (69%) were for and 545,867 (29%) were interviewed during intervention years (Supplementary Tables - In our primary individual-level analyses, among females, cash transfer programs were a with a lower probability of having a sexually transmitted infection within the last 12 mc (odds ratio [OR] 0.67, 95% confidence interval [CI] 0.50-0.91) and higher probability of had an HIV test within the last 12 months (OR 2.61, 95% CI 1.15-5.88) (Table 2, Suppl Tables 7-17). PEPFAR funding per capita (OR 1.48 per \$5 increase, 95% CI 1.01-1.30) HIV-related Global Fund disbursements per capita (OR 1.48 per \$5 increase, 95% CI 1. Among males, cash transfer programs were significantly associated with an increased probability of having had an HIV test within 12 Among males, cash transfer programs were significantly associated with an increased p of having an HIV test within the last 12 months (OR 3.19, 95% CI 2.45-4.15) (Table 2, Supplementary Tables 7-17). PEPFAR funding per capita (OR 1.22 per \$5 increase, 95% CI 1.09-1.36) were also associated with an increased probability of having an HIV test vitar 247 CI 1.09-1.36) were also associated with an increased probability of having an HIV test vitar 		
 control countries received PEPFAR funding at some point during the study period. We obtained individual survey data from 99 DHS and 6 AIS conducted in included cou during the study period – 24 during intervention years and 82 during comparison years 4 1). There were 1,885,733 survey respondents in total, of whom 1,295,177 (69%) were fr and 545,867 (29%) were interviewed during intervention years (Supplementary Tables - In our primary individual-level analyses, among females, cash transfer programs were a with a lower probability of having a sexually transmitted infection within the last 12 mc (odds ratio [OR] 0.67, 95% confidence interval [CI] 0.50-0.91) and higher probability o had an HIV test within the last 12 months (OR 2.61, 95% CI 1.15-5.88) (Table 2, Suppl Tables 7-17). PEPFAR funding per capita (OR 1.14 per \$5 increase, 95% CI 1.01-1.30) HIV-related Global Fund disbursements per capita (OR 1.48 per \$5 increase, 95% CI 1. Among males, cash transfer programs were significantly associated with an increased probability of having an HIV test within the last 12 months (OR 3.19, 95% CI 2.45-4.15) (Table 2, Supplementary Tables 7-17). PEPFAR funding per capita (OR 1.22 per \$5 increase, 95% CI 1.09-1.36) were also associated with an increased probability of having an HIV test v 	230	disbursements during the study period, and 16 (76%) intervention countries relative to 8 (38%)
We obtained individual survey data from 99 DHS and 6 AIS conducted in included cou during the study period – 24 during intervention years and 82 during comparison years of 1). There were 1,885,733 survey respondents in total, of whom 1,295,177 (69%) were fr and 545,867 (29%) were interviewed during intervention years (Supplementary Tables - In our primary individual-level analyses, among females, cash transfer programs were a with a lower probability of having a sexually transmitted infection within the last 12 mc (odds ratio [OR] 0.67, 95% confidence interval [CI] 0.50-0.91) and higher probability of had an HIV test within the last 12 months (OR 2.61, 95% CI 1.15-5.88) (Table 2, Suppl Tables 7-17). PEPFAR funding per capita (OR 1.14 per \$5 increase, 95% CI 1.01-1.30) HIV-related Global Fund disbursements per capita (OR 1.48 per \$5 increase, 95% CI 1. were also associated with an increased probability of having had an HIV test within 12 Among males, cash transfer programs were significantly associated with an increased p of having an HIV test within the last 12 months (OR 3.19, 95% CI 2.45-4.15) (Table 2, Supplementary Tables 7-17). PEPFAR funding per capita (OR 1.22 per \$5 increase, 95% 1.12-1.32) and HIV-related Global Fund disbursements per capita (OR 1.22 per \$5 increase, 95% Lincrease,	231	control countries received PEPFAR funding at some point during the study period.
 during the study period – 24 during intervention years and 82 during comparison years in 1). There were 1,885,733 survey respondents in total, of whom 1,295,177 (69%) were for and 545,867 (29%) were interviewed during intervention years (Supplementary Tables - In our primary individual-level analyses, among females, cash transfer programs were a with a lower probability of having a sexually transmitted infection within the last 12 more (odds ratio [OR] 0.67, 95% confidence interval [CI] 0.50-0.91) and higher probability of had an HIV test within the last 12 months (OR 2.61, 95% CI 1.15-5.88) (Table 2, Suppl Tables 7-17). PEPFAR funding per capita (OR 1.14 per \$5 increase, 95% CI 1.01-1.30) HIV-related Global Fund disbursements per capita (OR 1.48 per \$5 increase, 95% CI 1. were also associated with an increased probability of having had an HIV test within 12. Among males, cash transfer programs were significantly associated with an increased period of having an HIV test within the last 12 months (OR 3.19, 95% CI 2.45-4.15) (Table 2, Supplementary Tables 7-17). PEPFAR funding per capita (OR 1.22 per \$5 increase, 95% 1.12-1.32) and HIV-related Global Fund disbursements per capita (OR 1.22 per \$5 increase, 95% 1.12-1.32) and HIV-related Global Fund disbursements per capita (OR 1.22 per \$5 increase, 95% 1.12-1.32) and HIV-related Global Fund disbursements per capita (OR 1.22 per \$5 increase, 95% 1.12-1.36) were also associated with an increased probability of having an HIV test within 12 test within 12 test within the last 12 months (OR 3.19, 95%) (OR 1.22 per \$5 increase, 95% 	232	We obtained individual survey data from 99 DHS and 6 AIS conducted in included countries
 1). There were 1,885,733 survey respondents in total, of whom 1,295,177 (69%) were for and 545,867 (29%) were interviewed during intervention years (Supplementary Tables 4). In our primary individual-level analyses, among females, cash transfer programs were a with a lower probability of having a sexually transmitted infection within the last 12 mot (odds ratio [OR] 0.67, 95% confidence interval [CI] 0.50-0.91) and higher probability of had an HIV test within the last 12 months (OR 2.61, 95% CI 1.15-5.88) (Table 2, Suppl Tables 7-17). PEPFAR funding per capita (OR 1.14 per \$5 increase, 95% CI 1.01-1.30) HIV-related Global Fund disbursements per capita (OR 1.48 per \$5 increase, 95% CI 1. were also associated with an increased probability of having had an HIV test within 12 Among males, cash transfer programs were significantly associated with an increased p of having an HIV test within the last 12 months (OR 3.19, 95% CI 2.45-4.15) (Table 2, Supplementary Tables 7-17). PEPFAR funding per capita (OR 1.22 per \$5 increase, 95% CI 1.12-1.32) and HIV-related Global Fund disbursements per capita (OR 1.22 per \$5 increase, 95% CI 1.12-1.36) were also associated with an increased probability of having an HIV test 4 	233	during the study period – 24 during intervention years and 82 during comparison years (Figure
 and 545,867 (29%) were interviewed during intervention years (Supplementary Tables - In our primary individual-level analyses, among females, cash transfer programs were a with a lower probability of having a sexually transmitted infection within the last 12 mc (odds ratio [OR] 0.67, 95% confidence interval [CI] 0.50-0.91) and higher probability o had an HIV test within the last 12 months (OR 2.61, 95% CI 1.15-5.88) (Table 2, Suppl Tables 7-17). PEPFAR funding per capita (OR 1.14 per \$5 increase, 95% CI 1.01-1.30) HIV-related Global Fund disbursements per capita (OR 1.48 per \$5 increase, 95% CI 1. were also associated with an increased probability of having had an HIV test within 12 Among males, cash transfer programs were significantly associated with an increased p of having an HIV test within the last 12 months (OR 3.19, 95% CI 2.45-4.15) (Table 2, Supplementary Tables 7-17). PEPFAR funding per capita (OR 1.22 per \$5 increase, 95% 1.12-1.32) and HIV-related Global Fund disbursements per capita (OR 1.22 per \$5 increase, 95% I.12-1.36) were also associated with an increased probability of having an HIV test v last 12 months. 	234	1). There were 1,885,733 survey respondents in total, of whom 1,295,177 (69%) were female
In our primary individual-level analyses, among females, cash transfer programs were a with a lower probability of having a sexually transmitted infection within the last 12 mc (odds ratio [OR] 0.67, 95% confidence interval [CI] 0.50-0.91) and higher probability o had an HIV test within the last 12 months (OR 2.61, 95% CI 1.15-5.88) (Table 2, Suppl Tables 7-17). PEPFAR funding per capita (OR 1.14 per \$5 increase, 95% CI 1.01-1.30) HIV-related Global Fund disbursements per capita (OR 1.48 per \$5 increase, 95% CI 1. were also associated with an increased probability of having had an HIV test within 12 Among males, cash transfer programs were significantly associated with an increased p of having an HIV test within the last 12 months (OR 3.19, 95% CI 2.45-4.15) (Table 2, Supplementary Tables 7-17). PEPFAR funding per capita (OR 1.22 per \$5 increase, 95% 1.12-1.32) and HIV-related Global Fund disbursements per capita (OR 1.22 per \$5 increase, 95% CI 1.09-1.36) were also associated with an increased probability of having an HIV test y last 12 months.	235	and 545,867 (29%) were interviewed during intervention years (Supplementary Tables 4-6).
 with a lower probability of having a sexually transmitted infection within the last 12 mc (odds ratio [OR] 0.67, 95% confidence interval [CI] 0.50-0.91) and higher probability o had an HIV test within the last 12 months (OR 2.61, 95% CI 1.15-5.88) (Table 2, Suppl Tables 7-17). PEPFAR funding per capita (OR 1.14 per \$5 increase, 95% CI 1.01-1.30) HIV-related Global Fund disbursements per capita (OR 1.48 per \$5 increase, 95% CI 1. were also associated with an increased probability of having had an HIV test within 12 Among males, cash transfer programs were significantly associated with an increased p of having an HIV test within the last 12 months (OR 3.19, 95% CI 2.45-4.15) (Table 2, Supplementary Tables 7-17). PEPFAR funding per capita (OR 1.22 per \$5 increase, 95% 1.12-1.32) and HIV-related Global Fund disbursements per capita (OR 1.22 per \$5 increase, 95% CI 1.09-1.36) were also associated with an increased probability of having an HIV test v 	236	In our primary individual-level analyses, among females, cash transfer programs were associated
 (odds ratio [OR] 0.67, 95% confidence interval [CI] 0.50-0.91) and higher probability of had an HIV test within the last 12 months (OR 2.61, 95% CI 1.15-5.88) (Table 2, Suppl Tables 7-17). PEPFAR funding per capita (OR 1.14 per \$5 increase, 95% CI 1.01-1.30) HIV-related Global Fund disbursements per capita (OR 1.48 per \$5 increase, 95% CI 1. were also associated with an increased probability of having had an HIV test within 12 Among males, cash transfer programs were significantly associated with an increased p of having an HIV test within the last 12 months (OR 3.19, 95% CI 2.45-4.15) (Table 2, Supplementary Tables 7-17). PEPFAR funding per capita (OR 1.22 per \$5 increase, 95% 1.12-1.32) and HIV-related Global Fund disbursements per capita (OR 1.22 per \$5 increase, 95% CI 1.09-1.36) were also associated with an increased probability of having an HIV test v 	237	with a lower probability of having a sexually transmitted infection within the last 12 months
 had an HIV test within the last 12 months (OR 2.61, 95% CI 1.15-5.88) (Table 2, Supple Tables 7-17). PEPFAR funding per capita (OR 1.14 per \$5 increase, 95% CI 1.01-1.30) HIV-related Global Fund disbursements per capita (OR 1.48 per \$5 increase, 95% CI 1. were also associated with an increased probability of having had an HIV test within 12 Among males, cash transfer programs were significantly associated with an increased p of having an HIV test within the last 12 months (OR 3.19, 95% CI 2.45-4.15) (Table 2, Supplementary Tables 7-17). PEPFAR funding per capita (OR 1.22 per \$5 increase, 95% 1.12-1.32) and HIV-related Global Fund disbursements per capita (OR 1.22 per \$5 increase, 95% CI 1.09-1.36) were also associated with an increased probability of having an HIV test v last 12 months. 	238	(odds ratio [OR] 0.67, 95% confidence interval [CI] 0.50-0.91) and higher probability of having
 Tables 7-17). PEPFAR funding per capita (OR 1.14 per \$5 increase, 95% CI 1.01-1.30) HIV-related Global Fund disbursements per capita (OR 1.48 per \$5 increase, 95% CI 1. were also associated with an increased probability of having had an HIV test within 12 Among males, cash transfer programs were significantly associated with an increased p of having an HIV test within the last 12 months (OR 3.19, 95% CI 2.45-4.15) (Table 2, Supplementary Tables 7-17). PEPFAR funding per capita (OR 1.22 per \$5 increase, 95% 1.12-1.32) and HIV-related Global Fund disbursements per capita (OR 1.22 per \$5 increase, 95% CI 1.09-1.36) were also associated with an increased probability of having an HIV test v 	239	had an HIV test within the last 12 months (OR 2.61, 95% CI 1.15-5.88) (Table 2, Supplementary
 HIV-related Global Fund disbursements per capita (OR 1.48 per \$5 increase, 95% CI 1. were also associated with an increased probability of having had an HIV test within 12 Among males, cash transfer programs were significantly associated with an increased p of having an HIV test within the last 12 months (OR 3.19, 95% CI 2.45-4.15) (Table 2, Supplementary Tables 7-17). PEPFAR funding per capita (OR 1.22 per \$5 increase, 95% 1.12-1.32) and HIV-related Global Fund disbursements per capita (OR 1.22 per \$5 increase, 95% CI 1.09-1.36) were also associated with an increased probability of having an HIV test with an increased probability of having and HIV test with an increased probability of having and HIV test with an increased probability of having and HIV test with an increased p	240	Tables 7-17). PEPFAR funding per capita (OR 1.14 per \$5 increase, 95% CI 1.01-1.30) and
 were also associated with an increased probability of having had an HIV test within 12 Among males, cash transfer programs were significantly associated with an increased p of having an HIV test within the last 12 months (OR 3.19, 95% CI 2.45-4.15) (Table 2, Supplementary Tables 7-17). PEPFAR funding per capita (OR 1.22 per \$5 increase, 95% 1.12-1.32) and HIV-related Global Fund disbursements per capita (OR 1.22 per \$5 increase) CI 1.09-1.36) were also associated with an increased probability of having an HIV test v last 12 months. 	241	HIV-related Global Fund disbursements per capita (OR 1.48 per \$5 increase, 95% CI 1.18-1.84)
Among males, cash transfer programs were significantly associated with an increased p of having an HIV test within the last 12 months (OR 3.19, 95% CI 2.45-4.15) (Table 2, Supplementary Tables 7-17). PEPFAR funding per capita (OR 1.22 per \$5 increase, 959 1.12-1.32) and HIV-related Global Fund disbursements per capita (OR 1.22 per \$5 incre CI 1.09-1.36) were also associated with an increased probability of having an HIV test v last 12 months.	242	were also associated with an increased probability of having had an HIV test within 12 months.
 of having an HIV test within the last 12 months (OR 3.19, 95% CI 2.45-4.15) (Table 2, Supplementary Tables 7-17). PEPFAR funding per capita (OR 1.22 per \$5 increase, 95% 1.12-1.32) and HIV-related Global Fund disbursements per capita (OR 1.22 per \$5 increase) CI 1.09-1.36) were also associated with an increased probability of having an HIV test v last 12 months. 	243	Among males, cash transfer programs were significantly associated with an increased probability
 Supplementary Tables 7-17). PEPFAR funding per capita (OR 1.22 per \$5 increase, 950 1.12-1.32) and HIV-related Global Fund disbursements per capita (OR 1.22 per \$5 increase) CI 1.09-1.36) were also associated with an increased probability of having an HIV test v last 12 months. 	244	of having an HIV test within the last 12 months (OR 3.19, 95% CI 2.45-4.15) (Table 2,
 1.12-1.32) and HIV-related Global Fund disbursements per capita (OR 1.22 per \$5 increased CI 1.09-1.36) were also associated with an increased probability of having an HIV test last 12 months. 	245	Supplementary Tables 7-17). PEPFAR funding per capita (OR 1.22 per \$5 increase, 95% CI
 CI 1.09-1.36) were also associated with an increased probability of having an HIV test last 12 months. 	246	1.12-1.32) and HIV-related Global Fund disbursements per capita (OR 1.22 per \$5 increase, 95%
248 last 12 months.	247	CI 1.09-1.36) were also associated with an increased probability of having an HIV test within the
	248	last 12 months.

In our primary country-level analyses, cash transfer programs were associated with a reduction in
new HIV infections (incidence rate ratio [IRR] 0.94, 95% CI 0.89-0.99), but not with the
proportion of people with HIV receiving antiretroviral therapy (5.0%, 95% CI -0.2-10.1) or

It is made available under a CC-BY-NC-ND 4.0 International license .

252	AIDS-related deaths (IRR 0.99, 95% CI 0.95-1.03). In the same models, PEPFAR funding per
253	capita was associated with a reduction in AIDS-related deaths (IRR 0.98 per \$5 increase, 95% CI
254	0.97-0.99) and an increase in the proportion of people with HIV receiving antiretroviral therapy
255	(2.6% per \$5 increase, 95% CI 1.7-3.5), results that are consistent with an earlier analysis of the
256	relationship between PEPFAR and HIV outcomes. ⁴⁴ PEPFAR funding per capita was not
257	associated with new HIV infections (IRR 1.00 per \$5 increase, 95% CI 0.99-1.01). In addition,
258	HIV-related Global Fund disbursements per capita were associated with an increase in the
259	proportion of people with HIV receiving antiretroviral therapy (3.3% per \$5 increase, 95% CI
260	0.4-6.2), but not with new HIV infections (IRR 0.99 per \$5 increase, 95% CI 0.98-1.00) or
261	AIDS-related deaths (IRR 0.99 per \$5 increase, 95% CI 0.98-1.01).
262	We next evaluated associations between cash transfer programs and country-level outcomes over
263	time (Figure 2). In fully adjusted models, we found that new HIV infections were significantly
264	lower in the first year of the cash transfer program (IRR 0.94, 95% CI 0.89-0.99). While the
265	effects on new infections became larger in subsequent years after the introduction of cash
266	transfer programs, they were less precisely estimated over time as a result of declining numbers
267	of observations and were no longer significant after the second year of the cash transfer program.
268	There were no significant changes in AIDS-related deaths during the first year of the cash
269	transfer program (IRR 0.99, 95% CI 0.95-1.03), consistent with our primary analysis. However,
270	we found significant reductions in AIDS-related deaths by the second year of the cash transfer
271	program (IRR 0.91, 95% CI 0.83-0.99), with larger reductions over time that peaked in the ninth
272	year of the cash transfer program (IRR 0.75, 95% CI 0.57-0.99). Similarly, there was no
273	significant change in the proportion of people with HIV receiving antiretroviral therapy on the

medRxiv preprint doi: https://doi.org/10.1101/2021.12.16.21267921; this version posted December 17, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

274	first year of the cash transfer program (0.8%, 95% CI -1.0%-2.5%), but we found a significant
275	increase by the second year (3.0%, 95% CI 0.3-5.7), with larger increases over time.
276	In the interaction analysis, the effects of cash transfer programs were greater in higher
277	prevalence countries for the outcomes of an HIV test in the last 12 months among females
278	(p<0.0001) and males (p<.0001), and in lower prevalence countries for new HIV infections
279	(p=0.007) (Figure 3, Supplementary Table 21). The effects of cash transfer programs were
280	greater with higher coverage cash transfer programs for the outcomes of sexually transmitted
281	infection in the last 12 months among females (p<0.0001), having had an HIV test in the last 12
282	months among females (p=0.05) and males (p<.0001), and AIDS-related deaths (p=0.01).
283	When stratifying individual-level outcomes by wealth quintile, there were some modest trends
284	suggesting larger effects in poorer segments of the population, though these were inconsistent
285	and not definitively identified (Supplementary Figure 4). We confirmed that there was no
286	significant association between the presence of cash transfer programs and either PEPFAR
287	funding per capita or HIV-related Global Fund disbursements when these were included in our
288	primary model as outcomes (Supplementary Tables 22-23). Exclusion of individual countries did
289	not reveal possible outlier countries for any outcome except for HIV testing in females, for
290	which Guinea and Zambia were potentially outliers whose exclusion substantially changed the
291	estimated effect of cash transfers (Supplementary Tables 24-27).
292	Our fully adjusted models to test whether intervention and comparison countries had similar
293	trends in outcomes before the introduction of cash transfers in a given country showed no
294	differences between countries for the individual-level outcome of having a sexually transmitted
295	infection in the last 12 months for females (OR 0.98, 95% CI 0.92-1.04) or males (OR 0.99, 95%

It is made available under a CC-BY-NC-ND 4.0 International license .

296	CI 0.95-1.02), or for the country-level outcome of new HIV infections (IRR 0.99, 95% CI 0.96-
297	1.02) (Supplementary Tables 28-30). There were small, significant differences of opposite
298	magnitude in trends in outcomes before the introduction of cash transfers for the individual-level
299	outcome of having an HIV test within the prior 12 months for females (OR 0.81, 95% CI 0.81-
300	0.82) and males (OR 1.27, OR 1.01-1.12) (Supplementary Tables 31-32). There were no
301	discernible differences in outcomes between intervention and control countries in the four years
302	prior to the cash transfer period in our temporal analysis of country-level (Figure 2) or
303	individual-level outcomes (Supplementary Figures 5-6) except for the HIV testing outcome
304	among males, where there was some visual evidence of differential pre-trends in cash transfer
305	countries.

Additional analyses suggested that the effect of cash transfers was heterogeneous over time but
that any resultant bias was likely small (Supplementary Appendix, Supplementary Figures 7-8,
Supplementary Tables 33-34).

309 Discussion

310 In this study of 42 countries with generalized HIV epidemics of varying magnitude across three 311 continents from 1996 to 2019, we found that sizeable cash transfer programs were associated 312 with important improvements in HIV-related outcomes at both the population and individual 313 levels. These included an immediate reduction in new HIV infections and delayed improvements 314 in both AIDS-related deaths and the proportion of people with HIV receiving antiretroviral 315 therapy, with benefits that grew larger over time. Among individuals, we found that cash transfer 316 programs were associated with a reduction in sexually transmitted infections (a key proxy 317 measure for risk of HIV transmission) among females, as well as large increases in recent HIV

It is made available under a CC-BY-NC-ND 4.0 International license .

testing among males and females, though there were small differential pre-trends for the HIV 318 319 testing outcome so this finding should be interpreted with some caution. Our interaction analyses 320 showed that cash transfer programs with greater numbers of beneficiaries had the largest effects 321 on HIV-related outcomes, suggesting an element of dose-response at the population level. We 322 also found that the relationship between cash transfer programs and HIV testing was strongest in 323 countries with higher baseline HIV prevalence, indicating the importance of the specific context 324 of a given country's HIV epidemic. To our knowledge, this is the first study to have combined 325 data from all countries with generalized HIV epidemics and studied the effects of large-scale 326 cash transfer programs.

327 While our findings are consistent with prior evidence from randomized controlled trials of cash transfer interventions that support the use of cash transfers for the prevention of HIV,^{20,45-47} and 328 along the HIV care continuum,²⁵⁻³⁴ there are several notable distinctions to consider when 329 330 interpreting our findings. First, the cash transfer programs considered in this study were 331 generally of larger scale and less HIV-specific than those studied in the randomized trials. 332 Second, almost all of the cash transfer interventions studied in randomized trials were 333 conditional on intermediary outcomes like school attendance, negative testing for sexually transmitted infections, HIV testing, or clinical follow up, whereas nearly 80% of the programs 334 335 considered in our analysis were unconditional. Our study thus provides evidence, across many 336 countries with generalized HIV epidemics, on the effects of primarily government-led cash 337 transfer programs. Third, by evaluating outcomes for entire populations (i.e. by including 338 individuals and households that did not receive transfers), our findings also capture the indirect 339 or spillover effects of these interventions. These spillover effects are likely to be important in the

It is made available under a CC-BY-NC-ND 4.0 International license .

340 context of an infectious disease with transmission dynamics and clinical outcomes that are341 heavily influenced by structural factors like poverty and food insecurity.

342 There are a number of hypothesized mechanisms by which cash transfer interventions could 343 improve HIV-related outcomes. By increasing economic well-being, empowerment among 344 women, and educational attainment, cash transfers may lead to lower risk sexual behaviors (as 345 evidenced in our analysis by a reduction in sexually transmitted infections), thus lowering the probability of acquiring or transmitting HIV.¹³ This plausibly includes a reduction in 346 transactional sex among women,⁴⁸ an important driver of HIV risk among adolescent girls and 347 young women in particular for which data were unavailable to consider in our analysis.⁵ Cash 348 349 transfer programs may also lead to improvements along the HIV care continuum (i.e., HIV 350 testing, clinic attendance, and antiretroviral adherence) through a direct economic mechanism 351 that reduces barriers to care and a psychological mechanism that promotes health-seeking behaviors through improvements in mental bandwidth.¹⁴ As a result, cash transfers may lead to 352 353 increases in HIV diagnoses (as evidenced in our analysis by increased HIV testing), engagement 354 in clinical care by people with HIV, and higher probability of receiving and adhering to 355 antiretroviral therapy with subsequent virologic suppression (as evidenced in our analysis by a 356 delayed increase in the proportion of people with HIV receiving antiretroviral therapy). This 357 would both directly improve clinical outcomes for people with HIV and reduce rates of 358 transmission because of the highly effective strategy of using HIV treatment as prevention, 359 commonly referred to as "Undetectable = Untransmittable" or "U=U." By supporting preventive 360 health behaviors, anti-poverty interventions like cash transfers can thus play an important role in 361 improving individual HIV outcomes and preventing HIV transmission by intervening proximally 362 to current efforts for HIV control, which are focused primarily at the health system level.

It is made available under a CC-BY-NC-ND 4.0 International license .

While previous analyses have used a similar design to study effects of programs like PEPFAR,
this study is the first to do so for a common anti-poverty program that a growing number of
LMICs are introducing as central features of their poverty reduction and social protection
strategies.⁴⁴ While not the primary objective of this study, our findings also suggest
improvements in HIV testing, population antiretroviral coverage, and AIDS-related deaths
related to PEPFAR and The Global Fund.

369 This study has several limitations. The cash transfer programs we considered were 370 heterogeneous in terms of target population, size of transfer, conditionality, and coverage. Due to 371 sample size limitations, we cannot precisely determine the relative importance of these other 372 features of cash transfer programs, although in our interaction analyses we do establish that 373 programs which covered more individuals tended to have larger effects. In particular, the relative 374 amount of the transfer is likely to influence any effect it has on health outcomes, but because of 375 variability of transfer size within many of the programs and inconsistent reporting we were 376 unable to meaningfully consider this in our analysis. While the DHS and AIS surveys do not 377 uniformly indicate whether participants received cash transfers, and thus we cannot separately 378 determine cash transfer program effects on beneficiaries and non-beneficiaries, our objective was 379 to evaluate the overall population-level effect of these programs, and it is plausible that the effects are larger on beneficiaries relative to non-beneficiaries. While we included country and 380 381 year fixed effects and used a difference-in-differences design, the possibility of residual 382 confounding related to unmeasured time-varying variables remains, though the robustness of our 383 results after controlling for the available time-varying country-specific variables suggests this 384 bias, if present, is minor. Specifically, there are country-specific policies that influence cash 385 transfer program coverage and uptake (e.g., outreach, enrollment procedures, ease of benefit

It is made available under a CC-BY-NC-ND 4.0 International license .

386 receipt). We attempted to control for these differences by including country fixed effects and the 387 World Bank Governance Indicators in regression models, but if these policies differed between 388 countries over time and were also associated with changes in HIV-related outcomes this may 389 influence our findings. Importantly, though, we were attempting to examine the effects of cash 390 transfer programs as they are delivered in the real world and would emphasize that 391 implementation failures would most likely bias our results towards the null. The study period we 392 considered was one of generally substantial expansion of HIV control programs, and the 393 relationship between cash transfer programs and HIV-related outcomes may differ in settings 394 with already established HIV care systems.

395 Conclusion

396 In this difference-in-differences study of 42 countries with generalized HIV epidemics from 397 1996 to 2019, we found that cash transfer programs were associated with an immediate reduction in new HIV infections, a delayed improvement in AIDS-related deaths and the proportion of 398 399 people with HIV receiving antiretroviral therapy, a reduction in sexually transmitted infections in 400 the last 12 months among females, and an increase in recent HIV testing among males and 401 females. Based on our results, experimental studies that further investigate the effects of 402 unconditional cash transfers on HIV incidence and other HIV prevention behaviors should be a priority for future research. This study also contributes to our understanding of the social 403 404 determinants of health, and suggests that HIV-related benefits should be included in cost-benefit 405 analyses of cash transfer programs. As countries expand cash transfer programs, particularly in 406 the context of the COVID-19 pandemic, these findings suggest that anti-poverty interventions 407 like cash transfers should receive greater attention as part of HIV control efforts, alongside the 408 already existing focus on expanding biomedical services.

It is made available under a CC-BY-NC-ND 4.0 International license .

409 Funding

410 None

411 Declaration of Interests

412 The authors declare no conflicts of interest.

413 Author Contribution Statement

- 414 AR and HT conceptualized and designed the study. AR conducted the primary analysis and
- 415 wrote the first draft of the manuscript, both with critical feedback from HT.

416 **References**

- 417 1. UNAIDS. UNAIDS Data 2019. <u>http://aidsinfo.unaids.org/</u> (accessed 1/11/21.
- 418 2. UNAIDS. Fast-track: ending the AIDS epidemic by 2030. *Geneva: UNAIDS* 2014.
- 419 3. UNAIDS. Social protection: a Fast-Track commitment to end AIDS. *Geneva: UNAIDS*420 2018.
- 421 4. Richterman A, Leandre F, Jerome JG, Tsai AC, Ivers LC. Mortality Over Long-term Follow-
- 422 up for People With HIV Receiving Longitudinal Care and Antiretroviral Therapy in Rural Haiti.
- 423 *Open Forum Infect Dis* 2020; **7**(8): ofaa328.
- Joint United Nations Programme on HIV/AIDS and STRIVE. Transactional sex and HIV
 risk: from analysis to action. Geneva, 2018.
- 426 6. Lopman B, Lewis J, Nyamukapa C, Mushati P, Chandiwana S, Gregson S. HIV incidence
- 427 and poverty in Manicaland, Zimbabwe: is HIV becoming a disease of the poor? *AIDS (London,*
- 428 England) 2007; **21 Suppl 7**(Suppl 7): S57-66.
- 429 7. Brodish PH. An association between neighbourhood wealth inequality and HIV
 430 prevalence in sub-Saharan Africa. *J Biosoc Sci* 2015; **47**(3): 311-28.
- 4318.Gaumer G, Sherafat-Kazemzadeh R, Jordan M, Nandakumar A. Wealth and wealth432inequality in adult HIV prevalence. J Glob Health Rep 2021: e2020105.
- 433 9. Eaton LA, Cain DN, Pitpitan EV, et al. Exploring the relationships among food insecurity,
- alcohol use, and sexual risk taking among men and women living in South African townships. J
 Prim Prev 2014; **35**(4): 255-65.
- 436 10. Singer AW, Weiser SD, McCoy SI. Does Food Insecurity Undermine Adherence to
- 437 Antiretroviral Therapy? A Systematic Review. *AIDS Behav* 2015; **19**(8): 1510-26.

438 11. Weiser SD, Tsai AC, Gupta R, et al. Food insecurity is associated with morbidity and

patterns of healthcare utilization among HIV-infected individuals in a resource-poor setting.
 AIDS (London, England) 2012; **26**(1): 67-75.

441 12. Aibibula W, Cox J, Hamelin A-M, McLinden T, Klein MB, Brassard P. Association Between

Food Insecurity and HIV Viral Suppression: A Systematic Review and Meta-Analysis. *AIDS and Behavior* 2017; **21**(3): 754-65.

444 13. Bastagli F, Hagen-Zanker J, Harman L, Barca V. Cash transfers: what does the evidence 445 say? London: Overseas Development Institute, 2016.

446 14. Mani A, Mullainathan S, Shafir E, Zhao J. Poverty Impedes Cognitive Function. *Science* 447 *(New York, NY)* 2013; **341**(6149): 976.

448 15. Weiser SD, Palar K, Hatcher AM, Young S, Frongillo EA, Laraia B. Food Insecurity and
449 Health: A Conceptual Framework. In: Ivers LC, ed. Food Insecurity and Public Health. Boca
450 Raton, Fla, USA: CRC Press; 2015.

451 16. Haushofer J, Fehr E. On the psychology of poverty. *Science (New York, NY)* 2014;
452 **344**(6186): 862.

453 17. Schilbach F, Schofield H, Mullainathan S. The Psychological Lives of the Poor. *Am Econ* 454 *Rev* 2016; **106**(5): 435-40.

- 455 18. Fernald LC, Gertler PJ, Neufeld LM. Role of cash in conditional cash transfer programmes
 456 for child health, growth, and development: an analysis of Mexico's Oportunidades. *Lancet* 2008;
 457 **371**(9615): 828-37.
- 458 19. Walque D, Fernald LC, Gertler PJ, Hidrobo H. Cash Transfers and Child and Adolescent
 459 Development. In: Bundy D, de Silva N, Horton S, Jamison DT, Patton G, eds. Disease Control
 460 Priorities. Third edition ed. Washington, DC: World Bank.

20. Baird SJ, Garfein RS, McIntosh CT, Ozler B. Effect of a cash transfer programme for
schooling on prevalence of HIV and herpes simplex type 2 in Malawi: a cluster randomised trial. *Lancet* 2012; **379**(9823): 1320-9.

- Pettifor A, MacPhail C, Hughes JP, et al. The effect of a conditional cash transfer on HIV
 incidence in young women in rural South Africa (HPTN 068): a phase 3, randomised controlled
 trial. *The Lancet Global health* 2016; 4(12): e978-e88.
- 467 22. Handa S, Halpern CT, Pettifor A, Thirumurthy H. The Government of Kenya's Cash
 468 Transfer Program Reduces the Risk of Sexual Debut among Young People Age 15-25. *PloS one*469 2014; 9(1): e85473.
- 470 23. Handa S, Angeles G, Abdoulayi S, Mvula P, Tsoka M. Malawi Social Cash Transfer

471 Program Endline Impact Evaluation Report: University of North Carolina Chapel Hill, 2016.

- 472 24. Socialprotection.org Programme Database.
- 473 <u>https://socialprotection.org/discover/programme</u> (accessed 1/11/21.
- 474 25. Fahey CA, Njau PF, Katabaro E, et al. Financial incentives to promote retention in care
- and viral suppression in adults with HIV initiating antiretroviral therapy in Tanzania: a three-arm randomised controlled trial. *The Lancet HIV* 2020; **7**(11): e762-e71.
- 477 26. Thornton RL. The Demand for, and Impact of, Learning HIV Status. *Am Econ Rev* 2008;
 478 **98**(5): 1829-63.
- 479 27. Kohler H-P, Thornton RL. Conditional cash transfers and HIV/AIDS prevention:
- 480 unconditionally promising? *The World Bank Economic Review* 2012; **26**(2): 165-90.

It is made available under a CC-BY-NC-ND 4.0 International license .

481 Kim HB, Haile B, Lee T. Promotion and Persistence of HIV Testing and HIV/AIDS 28. 482 Knowledge: Evidence From a Randomized Controlled Trial in Ethiopia. *Health Econ* 2017; 483 **26**(11): 1394-411. 484 29. Kranzer K, Simms V, Bandason T, et al. Economic incentives for HIV testing by 485 adolescents in Zimbabwe: a randomised controlled trial. The lancet HIV 2018; 5(2): e79-e86. Yotebieng M, Thirumurthy H, Moracco KE, et al. Conditional Cash Transfers to Increase 486 30. 487 Retention in PMTCT Care, Antiretroviral Adherence, and Postpartum Virological Suppression: A 488 Randomized Controlled Trial. Journal of acquired immune deficiency syndromes (1999) 2016; 72 489 **Suppl 2**(Suppl 2): S124-S9. 490 McCoy SI, Njau PF, Fahey C, et al. Cash vs. food assistance to improve adherence to 31. 491 antiretroviral therapy among HIV-infected adults in Tanzania. AIDS (London, England) 2017; 492 **31**(6): 815-25. 493 32. Emenyonu N, Muyindike W, Habyarimana J, et al. Cash transfers to cover clinic 494 transportation costs improve adherence and retention in care in a HIV treatment program in 495 rural Uganda. 17th conference on retroviruses and opportunistic infections; 2010; 2010. p. 16-496 9. 497 33. Linnemayr S, Stecher C, Mukasa B. Behavioral economic incentives to improve 498 adherence to antiretroviral medication. AIDS (London, England) 2017; 31(5): 719-26. 499 El-Sadr WM, Donnell D, Beauchamp G, et al. Financial Incentives for Linkage to Care and 34. 500 Viral Suppression Among HIV-Positive Patients: A Randomized Clinical Trial (HPTN 065). JAMA 501 Intern Med 2017; 177(8): 1083-92. 502 Thirumurthy H, Ndyabakira A, Marson K, et al. Financial incentives for achieving and 35. maintaining viral suppression among HIV-positive adults in Uganda: a randomised controlled 503 504 trial. The lancet HIV 2019; 6(3): e155-e63. 505 36. Maughan-Brown B, Smith P, Kuo C, et al. A Conditional Economic Incentive Fails to 506 Improve Linkage to Care and Antiretroviral Therapy Initiation Among HIV-Positive Adults in 507 Cape Town, South Africa. AIDS Patient Care STDS 2018; 32(2): 70-8. 508 Metsch LR, Feaster DJ, Gooden L, et al. Effect of Patient Navigation With or Without 37. 509 Financial Incentives on Viral Suppression Among Hospitalized Patients With HIV Infection and 510 Substance Use: A Randomized Clinical Trial. Jama 2016; 316(2): 156-70. 511 The World Bank. World Development Indicators. https://data.worldbank.org/data-38. 512 catalog/world-development-indicators (accessed 1/12/21. PEPFAR Panorama Spotlight: Financial Management. https://data.pepfar.gov/financial 513 39. 514 (accessed 2/11/21. 515 40. TheGlobalFund Data Service. https://data-service.theglobalfund.org/downloads 516 (accessed 1/12/21. 517 41. Goodman-Bacon A. Difference-in-differences with variation in treatment timing. Journal 518 of Econometrics 2021. 519 Callaway B, Sant'Anna PHC. Difference-in-Differences with multiple time periods. 42. 520 Journal of Econometrics 2020. 521 Jakiela P. Simple Diagnostics for Two-Way Fixed Effects. arXiv preprint arXiv:210313229 43. 522 2021. 523 Bendavid E, Bhattacharya J. The President's Emergency Plan for AIDS Relief in Africa: an 44. 524 evaluation of outcomes. Ann Intern Med 2009; 150(10): 688-95.

525 45. Björkman Nyqvist M, Corno L, De Walque D, Svensson J. Incentivizing safer sexual

behavior: evidence from a lottery experiment on HIV prevention. *American Economic Journal: Applied Economics* 2018; **10**(3): 287-314.

528 46. Karim A, Leask K, Kharsany A, al. e. Impact of conditional cash incentives on HSV-2 and

529 HIV prevention in rural South African high school students: results of CAPRISA 007 cluster

randomized trial. International AIDS Conference. Vancouver, Canada. TUAC0101LB; 2015.

531 47. de Walque D, Dow WH, Nathan R, et al. Incentivising safe sex: a randomised trial of

- conditional cash transfers for HIV and sexually transmitted infection prevention in rural
 Tanzania. *BMJ Open* 2012; **2**(1): e000747.
- 534 48. Cluver L, Boyes M, Orkin M, Pantelic M, Molwena T, Sherr L. Child-focused state cash
- 535 transfers and adolescent risk of HIV infection in South Africa: a propensity-score-matched case-
- 536 control study. *The Lancet Global health* 2013; **1**(6): e362-70.

538 **Table 1**. Characteristics of included countries that implemented a cash transfer program (or combination of programs) with greater

than 5% impoverished population coverage during the study period (1996-2019) compared to those that did not implement such

540 program(s).

	Intervention Countries N=21	Comparison Countries N=21	Total N=42	p-value
Population (1000s), 1996, median (IQR)	10,372 (2,786-21,032)	4,349 (1,663-7,251)	11,801 (2,948-25,876)	0.45
Region, N(%)				<.0001
Africa	16 (76)	20 (95)	36 (86)	
Latin America / Caribbean	3 (14)	1 (5)	4 (10)	
Asia	2 (10)	0 (0)	2 (5)	
HIV Prevalence, median (IQR)				
1996	4.1 (2.0-12.5)	1.7 (1.4-4)	2.8 (1.6-6.3)	0.007
2005	4.4 (1.7-12.0)	2.2 (1.4-4.0)	2.7 (1.4-6.2)	0.02
2019	3.2 (1.1-12.1)	2.0 (1.3-3.4)	2.4 (1.2-6.1)	0.04
Annual HIV Incidence per 100,000, median (IQR)				
1996	379 (160-988)	218 (128-377)	246 (145-484)	0.01
2005	237 (77-539)	130 (90-209)	153 (86-350)	0.06
2019	80 (26-273)	59 (40-106)	66 (38-172)	0.32
Annual AIDS-related Death Rate per 100,000, median (IQR)				
1996	137 (69-284)	87 (45-113)	94 (46-193)	0.01
2005	168 (83-546)	125 (73-147)	132 (74-272)	0.02
2019	47 (24-95)	38 (22-79)	47 (22-82)	0.27
Proportion of population receiving ART, median (IQR)				
2005	4 (3-7)	2 (1-6)	3 (2-7)	0.09
2019	74 (62-82)	57 (43-64)	64 (46-79)	0.01
PEPFAR recipient, N (%)	16 (76)	8 (38)	24 (57)	0.03
PEPFAR funding per capita, median (IQR)				
2005	0.0 (0.0-2.8)	0.0 (0.0-0.7)	0.0 (0.0-2.4)	0.57
2019	6.9 (0.3-9.2)	0.0 (0.0-3.2)	1.0 (0.0-8.2)	0.05
HIV Global Fund recipient, N (%)	21 (100)	21 (100)	42 (100)	n/a
HIV Global Fund disbursements per capita, median (IQR)				
2005	0.7 (0.2-1.6)	0.7 (0.3-1.1)	0.7 (0.2-1.6)	0.4
2019	1.4 (1.1-3.1)	1.4 (0.8-2.0)	1.4 (0.8-2.7)	0.13
World Bank Governance Indicators, 1996				

It is made available under a CC-BY-NC-ND 4.0 International license .

Stability and Violence, median (IQR) -0.4 (-0.90.1) -0.3 (-1.2 - 0.3) -0.4 (-1.1 - 0.1)	0.75
Voice and Accountability, median (IQR) -0.6 (-0.9 - 0.3) -0.9 (-1.30.2) -0.7 (-1.10.1)	0.19
Effectiveness, median (IQR) -0.7 (-1.00.2) -0.7 (-1.20.2) -0.7 (-1.10.2)	0.34
Rule of Law, median (IQR)-0.7 (-1.00.2)-0.8 (-1.3 - 0.0)-0.8 (-1.30.2)	0.56
Regulatory Quality, median (IQR) -0.3 (-1.0 - 0.1) -0.7 (-1.3 - 0.3) -0.5 (-1.1 - 0.2)	0.21

Outcomes	Cash Trar	nsfer Program	PEPFAR capita (per	Funding per • \$5 increase)	HIV-related Disburseme (per \$5	l Global Fund ents per capita increase)
	Effect Measure	95% CI	Effect Measure	95% CI	Effect Measure	95% CI
	Individual-level,	Females				
Age at sexual debut among youths, coefficient ¹	0.00	-0.09-0.10	0.03	-0.01-0.07	0.01	-0.09-0.12
Sexually transmitted infection within 12 months, odds ratio ¹	0.67	0.50 - 0.91	0.98	0.80-1.19	0.90	0.74-1.09
Greater than 1 sexual partner within 12 months, odds ratio ¹	1.04	0.75 - 1.46	1.17	0.89-1.54	0.88	0.67-1.15
HIV test within 12 months, odds ratio ¹	2.61	1.15 - 5.88	1.14	1.01-1.30	1.48	1.18-1.84
Condom use at last sex, odds ratio ¹	0.94	0.77-1.14	1.01	0.91-1.09	1.16	0.99-1.37
	Individual-level	l, Males				
Age at sexual debut among youths, coefficient ¹	-0.14	-0.28-0.01	0.04	-0.04-0.11	-0.023	-0.16-0.12
Sexually transmitted infection within 12 months, odds ratio ¹	1.10	0.85 - 1.43	1.01	0.90-1.13	1.02	0.80-1.31
Greater than 1 sexual partner within 12 months, odds ratio ¹	1.12	0.99 – 1.28	1.02	0.91-1.13	1.00	0.91-1.09
HIV test within 12 months, odds ratio ¹	3.19	2.45 - 4.15	1.22	1.12-1.32	1.22	1.09-1.36
Condom use at last sex, odds ratio ¹	0.88	0.75 - 1.04	1.02	0.96-1.07	1.00	0.89-1.14
Transactional sex within 12 months, odds ratio ¹	0.99	0.85 - 1.15	0.93	0.80-1.09	1.07	0.88-1.31
	Country-le	vel				
New HIV infections, incidence rate ratio ²	0.94	0.89 - 0.99	1.00	0.99-1.01	0.99	0.98-1.00
AIDS-related deaths, incidence rate ratio ²	0.99	0.95 - 1.03	0.98	0.97-0.99	0.99	0.98-1.01
Proportion of people with HIV receiving ART, coefficient ²	5.0	-0.2 - 10.1	2.6	1.7-3.5	3.3	0.4-6.2

541 **Table 2.** The relationship between cash transfer programs and individual- and country-level HIV-related outcomes.

¹ Multivariable models include cash transfer program, age, single marital status, education, wealth quintile, rural household setting,

and the country-level covariates GDP per capita, PEPFAR funding per capita, HIV-related Global Fund disbursements per capita, and
 three World Bank Governance Indicators: Corruption, Stability and Violence, and Voice and Accountability.

It is made available under a CC-BY-NC-ND 4.0 International license

It is made available under a CC-BY-NC-ND 4.0 International license

- ² Multivariable models include the country-level covariates GDP per capita, PEPFAR funding per capita, HIV-related Global Fund
- disbursements per capita, and three World Bank Governance Indicators: Corruption, Stability and Violence, and Voice and
- 547 Accountability.

It is made available under a CC-BY-NC-ND 4.0 International license

548 List of Figures

549 **Figure 1** - Proposed causal framework with directed acyclic graph (DAG) outlining potential relationships between large-scale cash

- transfer programs and HIV-related outcomes, mediated through an anti-poverty effect. The green box is the exposure of interest (cash
- transfer programs). The blue boxes are the HIV-related outcomes of interest, two more proximal (sex behaviors, HIV treatment
- 552 cascade) and two more distal (HIV incidence, AIDS-related deaths). The orange boxes are ancestors of both the exposure and the
- 553 outcomes (i.e., confounders). Underneath each box are the covariates used to measure the constructs within the boxes. Covariates from
- the DHS are individual-level, and all other covariates are country-level.
- Figure 2 Timeline of included countries, with the green line indicating the cash transfer period, and the colored dots indicating years
 during which a Demographic and Health Survey (DHS) was conducted.
- 557 Figure 3 Adjusted incidence rate ratios of new HIV infections and AIDS-related deaths, and adjusted change in the proportion of
- 558 proportion of people with HIV receiving antiretroviral therapy, as a function of year of the cash transfer period.
- **Figure 4** Interaction analysis of baseline HIV prevalence at the start of the cash transfer period (above or below the median, 3.7%)
- and impoverished population coverage of the cash transfer program(s) (above or below the median, 23%) for individual- (stratified by
- sex) and country-level outcomes, with adjusted odds ratios for individual-level outcomes and adjusted incidence rate ratios for
- 562 country-level outcomes, and p-values for interaction.







STI in last 12 months		1	
High prevalence		⊢	0.09
Low prevalence	H		
High coverage	$\leftarrow \bullet$		<.000
Low coverage			
Multiple sex partners in last 12 m	onths		
High prevalence	F		0.19
Low prevalence		••	
High coverage	⊢	• •	0.49
Low coverage		·	
HIV test in last 2 years			
High prevalence			·→ <.000
Low prevalence		•	
High coverage			→ 0.05
Low coverage		•	I
Condom use at last sex			
High prevalence		• • • • • • • • • • • • • • • • • • •	0.99
Low prevalence		—	
High coverage		•	0.18
Low coverage		⊢	
Males			
STI in last 12 months			
High prevalence		•	0.09
Low prevalence			
High coverage			0.68
Low coverage			
Multiple sex partners in last 12 m	onths		
High prevalence		⊢	0.98
Low prevalence			
High coverage			0.06
Low coverage			
HIV test in last 2 years			
High prevalence			·• <.000
Low prevalence			- -
High coverage			► <.000
Low coverage			
Condom use at last sex			
High prevalence		· • · · ·	0.48
Low prevalence		► ●	
High coverage		••	0.29
Low coverage		i€i	
Transactional sex in last 12 month	าร		
High prevalence		+ •	0.2
Low prevalence			
High coverage		•	0.17
Low coverage			
Country-level			
New HIV Infections			0.007
			0.007
High coverage			0.25
Low coverage		H O -1	0.25
AIDS-Related Deaths			
Ligh provolongo		⊢● 1	0.41
nigh prevalence			
Low prevalence		H H H	
Low prevalence High coverage		+ ● + + ● -	0.01